Evidence map›Paper›PMID 33550540›Full record

ArticleQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2021

Quality of life in patients with type 2 diabetes after switching to insulin degludec: results from a cross-sectional survey.

Chioma Uzoigwe, Michael Radin, Carol M Hamersky, Mitch DeKoven, Cassie Holt, Swapna Karkare, William H Polonsky

Open access · hybridAbstract read
In one paragraph

Article in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Concept analysis of diabetes-related quality of life.Health and quality of life outcomes · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Chioma UzoigweNovo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, NJ, 08536, USA. coms@novonordisk.com.ORCID http://orcid.org/0000-0002-6853-7117
Michael RadinNovo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, NJ, 08536, USA.
Carol M HamerskyNovo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, NJ, 08536, USA.
Mitch DeKovenIQVIA, Falls Church, VA, USA.
Cassie HoltIQVIA, New York, NY, USA.
Swapna KarkareIQVIA, Deerfield, IL, USA.
William H PolonskyBehavioral Diabetes Institute, San Diego, CA, USA.
Novo Nordisk (United States) · USIQVIA (United States) · USDeerfield (United States) · USUniversity of California San Diego · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeFive quality of life (QoL) domains are particularly important to patients with type 2 diabetes (T2D) using basal insulin-sense of physical well-being, sense of safety regarding hypoglycemia, sense of diabetes as burdensome, feelings of freedom and flexibility, and sleep quality.

methodsAn online survey assessed these QoL domains in adult patients with T2D in the USA who had switched from a previous basal insulin to insulin degludec (IDeg): modified versions of the World Health Organization (Five) Well-Being Index (WHO-5), Hypoglycemia Attitudes and Behavior Scale (HABS; confidence and anxiety subscales only), and Diabetes Distress Scale (DDS; emotional burden and regimen-related distress subscales only); three items assessing feelings of freedom and flexibility; and one item assessing sleep quality (hours of restful sleep). Patients rated each item for their previous basal insulin and currently while using IDeg. Correlations between sleep quality and the other QoL scales were also assessed.

resultsIn total, 152 patients completed the survey and were included in the study sample. Patients reported significantly improved scores while using IDeg on all WHO-5, DDS, HABS, feelings of freedom and flexibility item scores, and total raw/mean subscale scores (P < 0.0001). Patients also reported a significantly greater number of hours of restful sleep [mean (SD) 6.6 (2.0) vs. 5.5 (1.8); P < 0.0001]. Better sleep quality statistically significantly correlated with improved QoL in all other domains assessed.

conclusionsTreatment with IDeg after switching from a previous basal insulin was associated with statistically significant improvements in all QoL domains assessed.

Indexed as

AdultAgedAged, 80 and overCross-Sectional StudiesDiabetes Mellitus, Type 2FemaleHumansHypoglycemiaHypoglycemic AgentsInsulin, Long-ActingMaleMiddle AgedPsychometricsQuality of LifeYoung AdultHypoglycemic Agentsinsulin degludecInsulin, Long-ActingBasal insulinHypoglycemiaInsulin degludecInsulin glargineQuality of lifeType 2 diabetes

Identifiers

PMID33550540
PMCPMC8178133
OpenAlexW3128135074

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.